

<b>Clinical Trials Summary for out of hours Important Reference</b>
---

<b>Acronym study title</b>	BL13
<b>Study Details</b>	A RANDOMIZED PHASE II TRIAL ASSESSING TRIMODALITY THERAPY WITH OR WITHOUT ADJUVANT DURVALUMAB (MEDI4736) TO TREAT PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER
<b>Principal Investigator PI Sub PI's</b>	Professor Alison Birtle PI Dr Thompson, Dr Porter (yet to start) Dr Charnley & Dr Parikh
<b>Research Nurse Team</b>	Sirjana Devkota
<b>Drug therapy</b>	Trimodality therapy with or without Durvalumab (depending on which arm participant is randomised)
<b>In the event that a patient calls this hotline for advise</b>	If patient calls during Monday-Friday 8am-5pm contact 01772524656 and ask for research nurse for advice. For out of hour contact hotline. Guideline as per study protocol.